Octapharma mulls building hemophilia product plant in Russia

Independent Swiss biotech company Octapharma is considering building a plant for production of drugs for the treatment of hemophilia in Russia, reports The Pharma Letter’s local correspondent.

Currently the company is in search of a production site for the project, and is considering several options. Among the possible options are the Yaroslavl, Moscow and Kaluga regions. Financial and other details of the project are not disclosed.

According to Raymond Schutz, head of Octapharma’s department of management and technology transfer, the company puts high hopes on the development of its Russian business. However, much will depend on the ability of the company to hire high-skilled personnel and an opportunity to make a profit.